BCA
PCRX icon

Berman Capital Advisors’s Pacira BioSciences PCRX Stock Holding History

Berman Capital Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$1K Buy
30
+26
+650% +$1.5K ﹤0.01% 1931
2021
Q2 		$0 Sell
4
-87
-96% -$5.51K ﹤0.01% 2000
2021
Q1 		$6K Buy
91
+2
+2% +$143 ﹤0.01% 1223
2020
Q4 		$5K Buy
89
+4
+5% +$234 ﹤0.01% 1162
2020
Q3 		$5K Buy
+85
New +$4.94K ﹤0.01% 1050

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Berman Capital Advisors's PCRX Position: Q3 2021 in Review

Berman Capital Advisors increased its Pacira BioSciences (PCRX) stake by 650% in Q3 2021, buying an estimated $1.5K and bringing the position to 30 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1931.

Berman Capital Advisors first reported a position in PCRX in Q3 2020 and has held it in 5 quarters since. The position peaked at $6K in Q1 2021. 259 funds tracked by Wall St. Rank hold PCRX as of Q3 2021.

  • Berman Capital Advisors held 30 shares of Pacira BioSciences worth $1K as of Q3 2021.
  • Berman Capital Advisors bought 26 Pacira BioSciences shares in Q3 2021, an estimated $1.5K.
  • Pacira BioSciences made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1931 holding.
  • Berman Capital Advisors first reported a position in Pacira BioSciences in Q3 2020 and has held it in 5 quarters since.
  • Berman Capital Advisors's Pacira BioSciences position peaked at $6K in Q1 2021.
  • 259 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.